Funding Opportunities

Supports an integrated team science approach to discovering the causes of Parkinson's disease through the Morris K. Udall DCWoW program, extending the existing Udall Centers of Excellence by enabling collaborative, discovery-focused research not possible via standard grant mechanisms. Note that this is a forecasted Notice of Intent.

Supports extramural biomedical and human performance research and development through the U.S. Army Medical Research Acquisition Activity (USAMRAA), open to any eligible entity including universities, nonprofits, and businesses, with awards ranging from $750K to $50M. This is a multi-year rolling BAA covering FY23–FY28.

Planning grant for investigators new to the CCRP field to build foundational knowledge, skills, collaborations, and preliminary data on shared mechanisms of skin injury caused by chemical threats, with emphasis on vesicants and other chemicals of concern rather than clinical trials.

Supports basic and applied research proposals in areas of interest to the Army Applications Lab (AAL), welcoming submissions from universities, nonprofits, businesses, and foreign organizations focused on disruptive technologies and applications with Army relevance. This is a rolling BAA open to up to 1,000 expected awards across a wide range of science and technology research areas.

Supports research and development of medical countermeasures, enabling technologies, life cycle bioinformatics, and improved logistics tracking across the chemical, biological, radiological, and nuclear defense mission areas, welcoming proposals from educational institutions, nonprofits, and private industry. This is a rolling BAA under which unsolicited proposals may be submitted at any time while the announcement remains active.

BARDA’s primary funding mechanism for medical countermeasures across pandemics, CBRN threats, and emerging infectious diseases.

BARDA DRIVe mechanism supporting early-stage, high-impact health security innovations with phased funding up to ~$20M.

Supports foundational basic and applied scientific research proposals submitted to the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL), spanning research areas from basic research through advanced technology development to help achieve Army overmatch in future conflicts. This is a consolidated rolling BAA open to universities, nonprofits, businesses, and foreign organizations.

Supports military-civilian partnerships (MCPs) at high-acuity trauma centers by enabling military trauma teams to provide full-time trauma and acute care alongside civilian counterparts, with the goal of improving the nation's response to public health and medical emergencies. Up to 30 eligible 501(c)(3) hospitals/trauma centers may receive awards from the $4 million total program funding pool.

Supports basic research to inform toxicology of chemical warfare agents and toxic industrial chemicals with primary or secondary effects on the nervous system, generating results to elucidate toxicity mechanisms and advance therapeutic countermeasures for civilian mass exposure situations. This active grant program (PAR-25-077) is from NINDS/NIAID, with application due dates in September 2025 and 2026.

Supports basic and applied research across a broad range of soldier-focused science and technology areas including combat feeding, soldier protection and survivability, textile technologies, biomechanics, human factors, aerial delivery, simulation and training, and biotechnology. This rolling BAA is open to proposals from any eligible entity and covers the full spectrum of soldier effectiveness and expeditionary maneuver support research.

Supports cutting-edge, often disease-agnostic research programs through ARPA-H's Health Science Futures mission office, seeking solution summaries and proposals that remove scientific and technological limitations to advance the healthcare of the future through translational, real-world impact. Submissions are accepted on a rolling basis via the ARPA-H solutions portal at solutions.arpa-h.gov.

Supports fundamental research — across grants, cooperative agreements, and other transactions — aimed at countering chemical, biological, radiological, nuclear, and explosive (CBRNE) threats, with a total program funding pool of $500 million open to any eligible entity. This is a long-term rolling BAA.

Supports fundamental engineering research in neuroengineering, rehabilitation robotics, brain-inspired assistive or rehabilitative systems, theoretical or computational methods, and novel models of functional recovery that advance knowledge benefiting individuals with disabilities. This active NSF program (DARE) has standard deadline cycles for high-risk, high-reward proposals.

Supports short-term exploratory clinical trials in arthritis, musculoskeletal, and skin diseases, including first-in-human, Phase I, and Phase II studies of drugs, biologics, devices, and behavioral or rehabilitation interventions.

Supports basic, applied, and advanced AI research and development through the Army Artificial Intelligence Integration Center (AI2C), seeking whitepapers and proposals from universities, nonprofits, businesses, and foreign organizations on new technologies and translational approaches that advance Army AI capabilities. This is a forecasted opportunity.

Supports extramural biomedical research through a rolling broad agency announcement from the U.S. Army Medical Research and Development Command (USAMRDC), welcoming pre-applications and full proposals from eligible organizations on an ongoing basis. This is a multi-year BAA open to submissions across a wide range of military medical research topics.

Supports action-oriented research under the NIH HEAL Initiative that accelerates the translation of evidence-based addiction prevention, treatment, and recovery interventions into routine practice, addressing the opioid crisis and overdose deaths across individual, provider, community, and system levels.

Supports the commercialization of "deep technologies" rooted in foundational science and engineering discoveries by providing NSF-funded researchers with entrepreneurial education, mentoring, and funding to assess product-market fit and accelerate the translation of basic research into emerging products, processes, and services.

Supports rigorous mechanistic clinical trials investigating how mind and body interventions — such as mindfulness meditation, yoga, acupuncture, and massage — impact emotional well-being and its relationship to whole person health, using a two-phased R61/R33 funding mechanism.

Supports the development of non-addictive analgesic therapeutics, including small molecules and biologics, to treat pain and address the opioid crisis. It focuses on advancing promising candidates through optimization and early clinical development, using a milestone-driven, collaborative approach to prepare for human studies.

Supports research on nutrition across the lifespan, with a focus on addressing social determinants of health to improve outcomes and reduce disparities. It emphasizes rigorous, nursing-informed research to advance equitable nutrition and health for diverse populations.

Supports research on improving health systems to better integrate treatment for co-occurring opioid use disorder and chronic pain. It focuses on collaborative care models, implementation strategies, and scaling sustainable, integrated care delivery across health settings.

Support the advanced development and enhancement of emerging informatics technologies to improve data acquisition, analysis, and interpretation across the cancer research continuum. It prioritizes high-impact, user-friendly tools with strong plans for community engagement, dissemination, and adoption, targeting technologies beyond early prototyping but not yet widely used.

Support the advanced development and enhancement of emerging informatics technologies to improve data acquisition, analysis, and interpretation across the cancer research continuum. It prioritizes high-impact, user-friendly tools with strong plans for community engagement, dissemination, and adoption, targeting technologies beyond early prototyping but not yet widely used.

Supports a comprehensive strategy for human performance science and technology research through the Air Force Research Laboratory (AFRL) and U.S. Air Force School of Medicine (USAFSAM) CHEERS Multiple Authority Announcement (MAA), covering research from basic science to technology maturation and transition. This active DoD Air Force program (FA238424S2233) covers research in human enabling, enhancing, restoring, and sustaining capabilities.

Supports research across all technical areas under the Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) program, soliciting white papers (and potentially later proposals) from any eligible entity on experimental and developmental efforts in human effectiveness topics for national defense.

Supports development of targeted drug-delivery strategies to reach hard-to-access sites in the body, such as the brain, placenta, retina, or tumors. It focuses on using microphysiological systems to optimize delivery, evaluate biodistribution and off-target effects, confirm therapeutic activity, and identify the best route of administration.

Supports research on how environmental exposures influence gut-brain signaling to drive neurological conditions, including mental health and neurodegenerative diseases. It aims to develop gut-focused interventions and biomarkers to improve detection, prevention, and treatment of these conditions through multidisciplinary approaches.

Supports the development and translation of extracellular vesicle (EV)-based therapeutics for regenerative medicine applications. It focuses on advancing innovative EV technologies, including engineered and off-the-shelf therapies, to improve tissue repair and regeneration.

Supports small businesses in advancing previously funded projects toward commercialization through later-stage R&D, regulatory activities, and technical assistance. It focuses on bridging gaps not covered by earlier SBIR/STTR phases, helping technologies move closer to market readiness and real-world application.

Supports innovative approaches to advance therapeutic development for ultra-rare cancers, including pediatric and molecularly defined subsets. It emphasizes collaborative data infrastructure, novel clinical endpoints, real-world evidence, and innovative trial and treatment strategies to overcome challenges in developing therapies for small patient populations.

Supports military nursing research and evidence-based practice (EBP) projects through the TriService Nursing Research Program (TSNRP), with initial and follow-on research awards up to $500,000 and EBP projects up to $200,000. This active program has rolling deadlines for military nursing research applications.

Supports high-priority, time-sensitive military nursing research projects through the TriService Nursing Research Program (TSNRP) FY25 RAPID High Priority Awards, providing rapid funding for emerging nursing research needs across the Department of Defense. This active program supports applied military nursing science with expedited review and funding cycles.

Supports research and surveillance of travel-associated infectious diseases through a collaborative network of travel and tropical medicine providers. It aims to improve detection, prevention, and clinical management by generating actionable data to inform public health guidance and patient care.

Supports research to prevent and mitigate severe respiratory illness by studying epidemiology, prevention, treatment, and long-term outcomes of respiratory pathogens. It aims to strengthen preparedness infrastructure and improve public health and clinical outcomes, particularly for high-risk populations.

Supports research to develop and test causal hypotheses linking human behaviors to oral and systemic health outcomes in individuals with chronic conditions. It emphasizes multidisciplinary approaches to identify underlying mechanisms and generate findings that can inform future clinical interventions and disease management strategies.

Supports interdisciplinary, data-driven research to uncover the molecular and cellular mechanisms underlying resilience to Alzheimer’s disease and related dementias. It emphasizes integrating genomic, epidemiologic, and mechanistic approaches to identify predictors of resilience across diverse populations.

Supports establishment of a translational center to advance the use of digital health technologies data in Alzheimer’s disease and related dementias research. It focuses on developing infrastructure, tools, and best practices to enable secure integration, sharing, and reuse of multi-modal data for translational and clinical applications.

Supports preclinical and clinical research on the discovery and development of high-impact interventions — including medications and medical devices — to prevent and/or treat substance use disorders and overdose, with the goal of advancing candidate interventions toward regulatory approval or clinical adoption. This opportunity uses the two-phased UG3/UH3 cooperative agreement mechanism, with awards up to $3 million.

Supports multidisciplinary groups of scientists conducting clinical research on sensory and communication disorders through the NIDCD Clinical Research Center Grant (P50), advancing diagnosis, prevention, treatment, and amelioration of hearing, balance, smell, taste, voice, speech, and language disorders. This active grant program (PAR-25-445) uses standard application due dates.

Supports the development of computational tools, theories, models, and analytical methods for understanding dynamic brain circuits and neural computations — spanning from neurons to behavior — that will be made broadly accessible to the research community. The program aims to advance fundamental understanding of brain function and organization, with applications toward treatments for brain disorders such as Parkinson's disease and major depressive disorder.

Supports advanced development and validation of emerging technologies for cancer research, building on prior feasibility to enable broader adoption. It focuses on refining and rigorously validating innovative tools and methods that enhance cancer detection, diagnosis, treatment, and research capabilities.

Supports institutions in establishing Nutrition Obesity Research Centers (NORCs) that provide shared research infrastructure, pilot funding, and collaborative programs to enhance multidisciplinary research in nutrition and obesity. The goal is to improve the efficiency, productivity, and impact of existing research programs through coordinated core services and innovation support.

Supports research on how specific stroke events contribute to cognitive impairment and dementia in post-stroke populations, with the goal of identifying underlying mechanisms and risk factors. It is a limited competition for prior awardees, emphasizing collaborative, multidisciplinary studies to improve understanding and outcomes of post-stroke vascular cognitive impairment.

Supports multidisciplinary teams translating laboratory discoveries into drug, biologic, device, or combination therapeutics for visual system diseases through a milestone-driven R61/R33 award (up to 5 years). Projects must advance a single candidate through IND/IDE-enabling studies toward an FDA filing; clinical trials are not allowed.

Supports state-of-the-art, investigator-initiated translational research through P50 SPORE grants aimed at improving prevention, early detection, diagnosis, and treatment of organ-specific or related human cancers. The program funds research that must stem from human biology and include a translational endpoint within the project period, with an estimated total funding pool of $25 million across approximately 12 awards.

Supports multidisciplinary urology research centers that foster collaboration and serve as national resources for advancing urologic science. It aims to drive impactful research through coordinated efforts across institutions and disciplines.

Provides researchers access to biospecimens from major longitudinal studies to investigate genetic, environmental, and substance-related influences on health across the lifespan. It aims to maximize the scientific value of these datasets by supporting studies that advance understanding of brain development, substance use, and disease risk.

Provides seed funding to support early-stage and new investigators conducting innovative research at the intersection of substance use, HIV/AIDS, and related fields. It aims to generate preliminary data and new concepts that can lead to larger, more comprehensive research projects.

Supports research education programs that enhance the scientific training and research skills of psychiatry residents. It aims to build a stronger mental health research workforce through innovative, research-focused educational experiences.

Supports the development of innovative short courses to train students, trainees, and early-career investigators in cutting-edge mental health research methods. It aims to enhance research skills and capacity through educational programs focused on emerging tools, techniques, and approaches.

Supports highly collaborative center-based research in basic neuroscience and translational mental health to advance understanding of brain, behavior, and severe mental illness. It emphasizes integrated, high-impact teams using innovative approaches to uncover mechanisms of psychopathology and improve the scientific foundation for mental health research.

Provides access to a state-of-the-art Biological Testing Facility to support development of new contraceptive methods and reproductive health therapies. It is intended for investigators with innovative, validated approaches that are ready to advance toward future clinical development.

Supports clinical research projects that advance trial readiness for rare diseases by enabling the efficient movement of candidate therapeutics or diagnostics toward clinical trials, including through the development of rigorous biomarkers, clinical outcome assessment measures, or characterization of rare disease presentation and course. The goal is to increase the likelihood of success for future rare disease clinical trials.

Supports discovery and mechanistic research to advance understanding of cardiovascular disease in type 1 diabetes through a continuation of the CARE-T1D consortium, leveraging multi-omics and molecular approaches. This forecasted NOFO uses the U01 cooperative agreement mechanism.

Supports the formation of a Disorders of Gastrointestinal Interoception Consortium (DGIC) to advance research on GI motility disorders, including gastroparesis, through multidisciplinary clinical research centers using state-of-the-art technologies to identify biomarkers and novel therapeutic targets. This forecasted NOFO (RFA-DK-27-117) anticipates funding up to 6 Clinical Research Centers via cooperative agreement, with an estimated application deadline of November 1, 2026.

Supports the continuation of the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers, leveraging patient cohorts, biospecimens, and data science to characterize genetic, clinical, and environmental factors in IBD development and advance precision medicine. This forecasted NOFO (RFA-DK-27-116) uses the cooperative agreement mechanism, anticipates up to 9 awards totaling $6.4M, with an estimated application deadline of November 1, 2026.

Supports the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) by establishing a Data Coordinating Center (DCC) that manages participant enrollment, biospecimen collection, data coordination among Genomic Research Centers, and submission of data to central repositories. This forecasted NOFO (RFA-DK-27-124) uses the cooperative agreement mechanism with an estimated 1 award totaling $1.6M and a deadline of November 1, 2026.

Supports establishing a Scientific Data Research Center (SDRC) to coordinate collaboration among Clinical Research Centers, manage enrollment, biospecimen processing, and data submission to central repositories.

Supports early-stage investigators of exceptional creativity to propose novel, original, and insightful vision research with high impact potential through the NEI New Innovator Award (DP2 mechanism). This forecasted grant (PAR-26-087) anticipates 4 awards.

Supports interdisciplinary research networks through the U24 mechanism to advance biomedical research on resilience and health optimization, foster cross-training and collaborations, and generate preliminary data through small-scale pilot projects. This forecasted cooperative agreement (RFA-AT-26-001) anticipates 3 awards totaling $1.5M.

Supports interdisciplinary teams forming Centers of Excellence in Genomic Science (CEGS) to address challenging biomedical questions from a genomics perspective, developing highly innovative concepts, methods, tools, and technologies not achievable by standard R01s. This forecasted cooperative agreement (PAR-26-036) anticipates 2 awards totaling $5M.

Supports dissemination of NHGRI-funded genomic technologies by funding integrated toolkits containing reagents, hardware, annotated protocols, computational pipelines, and hands-on training to lower barriers to adoption of novel genomic tools by the scientific community. This forecasted grant (PAR-26-037) anticipates up to 15 awards with a ceiling of $50K each.

Supports the commercialization of "deep technologies" rooted in foundational science and engineering discoveries by providing NSF-funded researchers with entrepreneurial education, mentoring, and funding to assess product-market fit and accelerate the translation of basic research into emerging products, processes, and services. The program is open to U.S. institutions of higher education, with awards starting at $50,000 from a total program pool of $12 million.

Supports rigorous mechanistic clinical trials investigating how mind and body interventions — such as mindfulness meditation, yoga, acupuncture, and massage — impact emotional well-being and its relationship to whole person health, using a two-phased R61/R33 funding mechanism. The R61 phase establishes feasibility benchmarks, followed by the R33 phase for full-scale trials contingent on successful milestone completion.

Supports a pilot program to develop and apply AI models to address the complexity and heterogeneity of diabetes. It focuses on integrating data science and biomedical expertise to create, validate, and disseminate AI tools that accelerate diabetes research and enable more personalized approaches.

Seeks to fund approximately 5 awards totaling ~$3.745M to support a national network of centers providing resources, expertise, and pilot funding to advance nonmalignant hematology research.

Supports development of SCENT III electronic nose technologies that use volatile organic compound (VOC) signatures from human skin to create a noninvasive, real-time diagnostic platform for disease diagnosis and monitoring. This forecasted cooperative agreement (RFA-TR-26-001) uses NCATS Cures Acceleration Network authorities.

Supports development and validation of advanced 3-D tissue models for drug screening that structurally, biochemically, and mechanically mimic human tissue, requiring applicants to utilize the NCATS 3-D Bioprinting laboratory infrastructure. This forecasted cooperative agreement (RFA-TR-25-016) anticipates 2 awards totaling $1.6M.

Supports research determining whether and how breakthrough AI systems affect patient safety and how AI can be safely implemented in healthcare settings, balancing AI's potential to improve safety and efficiency against risks of patient harm. This active AHRQ grant program (PA-24-261) uses standard application due dates.

Supports development, testing, and evaluation of strategies and interventions to improve diagnostic safety and quality in the heterogeneous ambulatory care environment, addressing AHRQ's goal of improving patient safety through diagnosis. This active AHRQ grant program (PA-23-290) uses standard application due dates.

Supports research focused on understanding and improving diagnostic safety in ambulatory care by investigating the incidence and contributory factors of diagnostic errors across the array of ambulatory care services. This active AHRQ grant program (PA-23-291) uses standard application due dates.

Supports system-level research approaches to improve patient safety by improving healthcare worker safety and well-being, recognizing that patient safety cannot be fully achieved without addressing the safety and well-being of healthcare professionals. This active AHRQ grant program (PA-24-093) uses standard application due dates.

Supports health services research demonstration and dissemination grant applications (R18) focused on AHRQ priorities including improving healthcare quality, patient safety, healthcare delivery, practice improvement, and whole-person healthcare delivery across all settings and populations. This active AHRQ grant program (PA-24-156) uses standard application due dates.

Supports research building evidence about the characteristics and value of primary care that influence patient outcomes and advance health equity, such as care coordination, continuity, comprehensiveness, and trust, and how these can be improved to strengthen primary healthcare. This active AHRQ grant program (PA-24-205) uses standard application due dates.

Supports research advancing fundamental, process-level, and systems-level understanding of the Arctic's rapidly changing natural environment, social and cultural systems, including Arctic Natural Sciences, Arctic Social Sciences, Arctic System Science, Arctic Observing Network, and Polar Cyberinfrastructure. This active NSF solicitation (NSF 23-572) supports U.S. investigators studying the Arctic region and its connectivity with lower latitudes.

Supports Diabetes Research Centers that enhance collaboration and shared resources through required cores and a Pilot & Feasibility Program to advance diabetes, endocrine, and metabolic research.

Supports the development of models and related materials for studying human health and diseases through Resource-Related Research Projects (R24 Clinical Trials Not Allowed), enabling researchers to create new tools, animal models, technologies, and reagents. This active NIH grant program (RFA-OD-25-010) focuses on expanding research capacity for human health research.

Supports novel cutting-edge study designs using machine learning, artificial intelligence, and adaptive methods to discover individual-level health and function profiles that could enable personalized prevention plans for cognitive and brain health in older adults. This forecasted NIA grant program aims to advance precision aging research.

Supports various research and development projects across U.S. Army Corps of Engineers Engineer Research and Development Center (ERDC) laboratories including Coastal and Hydraulics, Geotechnical, Environmental, Information Technology, Cold Regions, Construction Engineering, and Geospatial Research. Active BAA (W912HZ26S0001) with application due date of January 1, 2027.

Supports improving the health and well-being of individuals with traumatic brain injuries (TBI) by streamlining access to critical resources, services, and supports, including information and referral services, resource facilitation, outreach and awareness, and screening and trainings to community stakeholders. This forecasted ACL grant program (HHS-2026-ACL-AOD-TBSG-0019) anticipates approximately 31 awards.

Supports multidisciplinary centers to determine 3-dimensional structures of molecules and molecular complexes involved in priority infectious diseases including HIV, focusing on biomolecular complexes that can be targeted to develop new medicines and diagnostic tests to prevent or treat infections. This forecasted NIAID cooperative agreement (RFA-AI-27-009) anticipates future announcement.

Supports a Clinical Research Network on Antimicrobial Resistance (AMR) to design, implement, and manage clinical research addressing key AMR clinical questions, including treatment limitations from resistant infections in vulnerable populations such as those with diabetes and cancer. This forecasted NIAID cooperative agreement (RFA-AI-27-005) has an estimated deadline of January 14, 2026.

Funds rolling Mini Evidence-Based Practice (EBP) projects, providing equipment and supplies to support military nurse-led EBP operational projects that foster warfighter readiness and military nursing care. Applications are accepted on a rolling basis through August 31, 2026, pending available funding.

Seeks to enable researchers to access its Biobank biospecimens for assays evaluating associations between biomarkers and chronic diseases, supporting precision medicine through biomarker discovery, validation, disease stratification, and multiomics integration. This forecasted opportunity supports the program's mission to accelerate research by leveraging data from over 1 million enrolled participants.

Two ambitious projects focused on rigorous functional validation of newly identified therapeutic targets for Alzheimer’s disease–related dementias, with the goal of de-risking translational research and accelerating development of new therapies. This forecasted opportunity favors cross-disciplinary teams able to build and validate target-modulation tools, models, and protocols in a phased, milestone-driven framework.

Small pilot projects that advance the Human Virome Program by validating and improving virome-related tools, expanding relevant cohorts or biospecimen sampling, and studying interactions between the human virome and host health. It is best suited to focused, collaborative projects that complement rather than duplicate existing consortium efforts and can deliver meaningful results on a limited scope with modest resources.

Supports a collaborative network to develop and clinically test novel therapies for glioblastoma, including agents that can cross the blood-brain barrier. It aims to accelerate drug development from late preclinical stages through early-phase clinical trials to improve treatment outcomes.

Supports early-stage development of innovative technologies for cancer research, focusing on proof-of-concept studies for new tools, assays, and platforms. It emphasizes high-impact, technically novel approaches that can enhance cancer detection, diagnosis, treatment, and overall research capabilities.

Supports enhancing bioengineering and biomedical imaging research capacity at Historically Black Colleges and Universities (HBCUs). It aims to strengthen innovation, training, and partnerships to increase competitiveness and advance technological development in health research.

Supports expansion of the NExUS Collaboratory to study neural cell populations and circuits involved in addiction and substance-related behaviors. It focuses on generating and integrating multimodal datasets, developing analytical tools, and advancing understanding of how neural ensembles encode addiction-related processes.

Supports exploratory, collaborative research on brain and nervous system disorders across the lifespan, with a focus on partnerships between U.S. and low- and middle-income country institutions. It aims to advance scientific understanding and develop innovative, cost-effective interventions addressing neurological and mental health conditions globally.

Provides early-stage investigators with a single, flexible grant to support all research within their lab aligned with NIGMS priorities. It aims to enhance funding stability, reduce administrative burden, and enable innovative, high-impact scientific research.

Supports applied research BAA focused on developing technologies for detection, protection, and response to CBRN threats.

Supporting innovative, high-impact research with clinical relevance, this congressionally directed program funds efforts to decrease risk, slow progression, and ease symptoms of Parkinson's disease. Administered by the Defense Health Agency, it encourages investigators to explore a wide range of biological, clinical, and therapeutic approaches across both preclinical and human research.

Fostering basic research that offers significant benefits to national warfighting and peacekeeping capabilities, this Air Force Office of Scientific Research opportunity supports work across engineering, information science, physical science, and biological science. Research is conducted within Air Force, university, and industry laboratories, with the goal of ensuring results transition to meet U.S. Air Force needs.

The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing.

Funds efforts to expand access to preventive health services for women and girls by strengthening screening programs, improving early detection, and enhancing care delivery systems across diverse and underserved settings. It is best aligned with integrated approaches that combine service delivery, workforce training, and community engagement to improve health outcomes.

Funds bio-behavioral surveillance among populations disproportionately affected by HIV, generating data on risk behaviors, testing patterns, and prevention service use to inform public health strategies. It is best aligned with rigorous, community-engaged approaches that support targeted interventions and program planning.

AFOSR's open BAA for basic research across Air Force priorities including engineering, information science, and physical and biological sciences. Supports university, nonprofit, and industry proposals aligned with national warfighting and peacekeeping capabilities.

DARPA rolling solicitation inviting innovative basic research concepts across all technical offices, including the Biological Technologies Office (BTO) and Defense Sciences Office (DSO). Abstracts accepted on a rolling basis through June 2027.

The CDMRP Reconstructive Transplant Research Program (RTRP) offers an FY26 anticipated Investigator-Initiated Research Award to advance the science and clinical practice of vascularized composite allotransplantation (VCA). Applications must address at least one focus area, including optimizing VCA immunosuppression, validating biomarkers and tools for monitoring graft rejection, advancing preservation strategies, or developing outcome measures spanning functional, patient-reported, and neurocognitive domains.

Supports studies with the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life, with awards up to $1 million in total costs over a maximum 3-year period of performance. Applications must address at least one FY26 RTRP Focus Area, require preliminary and/or published data, and require a Letter of Intent prior to full submission; clinical trials are not permitted under this mechanism.

Supports prototype-stage solutions that address military readiness, operational medicine, infectious disease threats, musculoskeletal injuries, pain management, and force health protection. Ideal projects have demonstrated feasibility, align with a specific military capability gap, and are focused on advancing deployable products, clinical solutions, or knowledge products rather than early-stage basic research.

Funds basic research, discovery, and preclinical development of highly effective vaccines for malaria and potentially other mosquito-borne diseases. Supports novel vaccine design approaches, including structure-based immunogen design and combination vaccines, to reduce parasite infection and malaria disease burden.

For teams that already have a working biomarker assay on human specimens and need to take it through analytical validation first, then clinical validation, so it can be used as an investigational assay in future cancer trials or studies. It is a good fit for later-stage assay validation projects with a clear cancer-related clinical context, strong multidisciplinary support, quantitative go/no-go milestones, and access to well-annotated specimens, but it is not for biomarker discovery, early technology development, or conducting a clinical trial itself.

Funds exploratory basic research on biological/genetic mechanisms of cancer health disparities in racial/ethnic and other underserved populations, with no clinical trials allowed and should clearly test biological mechanisms tied to disparities using relevant underserved-population biospecimens/models/datasets, and avoids nonresponsive topics like projects without a cancer disparities focus, age/sex disparities alone, or non-biological behavioral/social studies.

Funds research partnerships between academic investigators and industry (U01) to develop bioengineering solutions, leveraging industry resources and expertise to address complex biomedical challenges. Applications must propose collaboration between at least one academic researcher and one industry partner to advance bioengineering technologies toward clinical application.

Advances development of fit-for-purpose candidate biomarkers and composite biomarker panels for neurological and neuromuscular disorders, targeting more efficient clinical trials and improved clinical care decisions. Encompasses biomarker identification, confirmation using human samples or data, and clinical validation across disease settings.

Supports investigators with validated starting compounds to discover and develop novel in vivo chemical probes for brain targets relevant to the missions of NIA, NEI, NIDA, and NIMH, advancing understanding of biological processes and disease mechanisms in the nervous system. Clinical trial not allowed.

Supports early-stage, engineering-driven projects that test the feasibility and potential utility of new or improved bioengineering solutions for biomedical research, clinical care delivery, or accessibility challenges within the missions of NCI and NIDCR. It is best suited to innovative, multidisciplinary projects that generate proof-of-feasibility or preliminary development data for promising technologies, methods, or tools that could lead to meaningful advances in capability, performance, cost, or access.

Advancesearly exploratory, proof-of-concept studies on mechanisms by which bariatric surgery affects cancer risk, specifically to attract bariatric surgery researchers to study cancer-related outcomes rather than short-term endpoints like weight loss or diabetes.

Supports pilot testing of patient navigation models that divert non-urgent mental health needs from emergency departments by assessing acuity, supporting caregivers, and connecting families to appropriate services. Intended for established models with limited evidence or development and pilot testing of model components, rather than larger-scale or fully powered studies.

Supports planning for future large-scale eye and vision clinical trials or epidemiologic studies that address major causes of blindness, impaired vision, sight-threatening conditions, or vision rehabilitation needs. Funds protocol development, Manual of Procedures preparation, feasibility work, and recruitment planning. Clinical trial not allowed.

Supports vision-related secondary analyses of existing human data only—such as clinical trial, epidemiologic, EHR, registry, claims, or merged patient-level datasets—to address new questions distinct from the original study aims, with no new data collection or animal-data analysis allowed.

Supports new investigators in dental, oral, and craniofacial research with up to 2 years and $200,000 direct costs total ($100,000/year) for pilot, feasibility, or developmental projects meant to generate preliminary data for a later R01 or equivalent, and it does not allow clinical trials.

NIH Parent R21 exploratory/developmental research grant for early-stage, high-impact malaria research concepts. Standard NIH deadlines apply.

Third open period under the CHEERS MAA soliciting white papers on human effectiveness S&T areas. Issued as a Commercial Solutions Opening (CSO) under 10 U.S.C. 3458 — NOTE: this CSO mechanism is not grant-eligible (contract/OT only).

[FORECAST — est. post Sep 8, 2026; est. application due Nov 10, 2026, not yet open] Funds pilot projects that advance the Human Virome Program by validating and improving virome-related tools, expanding relevant cohorts or biospecimen sampling, and studying interactions between the human virome and host health. Best suited to focused, collaborative projects that complement rather than duplicate existing consortium efforts and can deliver meaningful results on a limited scope with modest resources.

Standing ARPA-H Mission Office ISO for preventative research that reduces the likelihood people become patients; accepted on a rolling basis for ideas outside the scope of existing programs/initiatives.

MTEC consortium-funded bridge financing to sustain member prototype projects awaiting follow-on government funding; ongoing RPP.

Standing ARPA-H Mission Office ISO for research addressing geography, distribution, manufacturing, data/information, and economies to promote equitable, scalable health solutions; rolling basis.

Supports exploratory and developmental research (R21) addressing diagnostic and treatment uncertainty for individuals monitored or treated under the James Zadroga 9/11 Health and Compensation Act, with potential to lead to breakthroughs in treatment effectiveness and diagnostic practices. This forecasted grant program (RFA-OH-26-015) anticipates approximately 60 awards.

Supports individuals conducting dissertation research as part of an accredited doctoral program, providing AHRQ funding to advance health services research undertaken to qualify for a research doctorate degree. This active AHRQ grant program (PA-23-196) uses standard application due dates.

Supports early-stage development of informatics technologies to improve data acquisition, management, and analysis across the cancer research continuum. It focuses on novel, user-friendly tools from initial prototyping through early dissemination, with an emphasis on impact, user engagement, and clear development milestones.

Forecasted NIH-wide parent award under the Unified Funding Strategy that provides stable, program-level (investigator-focused) support in place of project-specific grants, allowing established investigators to pursue and pivot across a body of work under a single, longer-duration award (R35 awards typically run up to roughly 7-8 years). Consolidates multiple project grants into one investigator-level mechanism. Specific NOFO number, eligibility, and budget caps will be defined when the full announcement posts. Broadly applicable across NIH institutes.

Supports innovative healthcare and public health research aligned with the Resilient Systems Office mission, with emphasis on technologies that improve the quality, effectiveness, and availability of care.

Funds projects that increase the scientific value of existing datasets for AI-enabled discovery: applying AI to feature extraction and metadata generation, building robust automated data pipelines, and augmenting/harmonizing datasets for interoperability, with required attention to data governance, security, and community contribution. Does not fund new data collection. Three tiers: Flagship, Impact, and Planning grants.

Establishes up to 10 state or multi-state regional consortia (led by institutions of higher education with industry, philanthropy, and state/local government partners) to expand researcher access to computing, data, and AI infrastructure and build the AI-for-science technical workforce. NSF funds consortium coordination, AI-infrastructure staff, and faculty/curriculum development (not the hardware itself); one award per state or region. Cooperative agreement.

FY26 CDMRP BCRP mechanism supporting promising research with high potential to make breakthroughs in breast cancer at Funding Levels 1 and 2 (Level 2 includes a Population Science Studies option); single PI or Initiating/Partnering PI (PPIO) allowed.

This solicitation will seek to fund development of therapeutics that treat dysregulated host responses to priority CBRN exposures, enabling effective intervention without rapid threat identification and in delayed-presentation scenarios. BARDA is particularly interested in broadly applicable products that preserve or restore physiological function, mitigate systemic injury, and improve clinical outcomes across multiple CBRN threat categories.

Supports a network of U.S. institutions conducting standardized, prospective surveillance of pediatric acute respiratory illness and acute gastroenteritis across inpatient and emergency care settings. Projects will generate estimates of influenza, rotavirus, RSV, and other prevention-product effectiveness, with optional outpatient surveillance and immunologic studies.

Supports continued operation of the U.S. Influenza Vaccine Effectiveness Network to evaluate influenza and other respiratory pathogen vaccine effectiveness through prospective surveillance, systematic testing, and related research. The multi-component program also supports coordination and surge capacity, household transmission studies, and immunogenicity research.

Supports extension of data collection, follow-up, and analysis of existing breast cancer clinical studies to increase their clinical impact.

Supports highly innovative basic or applied research aligned with Department of the Navy science and technology priorities. The program seeks creative research with long-term potential to advance naval capabilities, national security, and warfighter effectiveness.

Supports translational and clinical research to improve pharmacology and therapeutics for pregnant and lactating women, infants, children, and adolescents. Research may advance precision medicine tools, develop or optimize medications, improve understanding of drug safety and effectiveness, and expand evidence-based interventions for these populations.

The TRC4 (Trauma Research and Combat Casualty Care Collaborative) 2027 Grant Program, a joint UT System/DoD initiative, offers four mechanisms (Early Career Mentored, Proof of Concept, Preclinical/Translational, and Clinical Research Awards ranging from $100K–$500K total costs) for trauma-focused research spanning pre-hospital care, wound management, TBI, burn, blood products/resuscitation, and related areas. LOIs are due January 5, 2027, full proposals March 31, 2027, with eligibility limited to PIs holding a primary appointment at a University of Texas System institution.

Supports NCI-funded research to investigate and mitigate how biospecimen preanalytical variability — in tumor tissue biopsies, blood/liquid biopsies, and other specimens — affects the reliability of clinically relevant biomarker assays. Best suited to projects that generate evidence-based specimen-handling standards to strengthen clinical assay development and analytical validation.

Supports international health security efforts that strengthen partner-country capabilities for biosurveillance, laboratory systems, outbreak preparedness, and response. Projects may also advance biosafety, biosecurity, and sustainable scientific partnerships with global partners.

Supports research on radiological/nuclear or chemical exposures, including relevant injury models, diagnostic tools, biomarkers and triage technologies, and development of medical countermeasures to mitigate or treat acute and delayed injuries. Clinical trials are not allowed.

Establishes NIAID's Infectious Diseases Clinical Trials Network of Clinical Trial Evaluation Units (CTEUs) and one optional Network Coordination Center (NCC) to evaluate therapeutics, vaccines, biologics, diagnostics and devices for emerging and chronic infections. Each CTEU must include an applicant-controlled clinical trial site, clinic, clinical laboratory and pharmacy.

Supports investigator-initiated NINDS clinical trials addressing neurological diseases and care, including early- and middle-phase exploratory trials as well as later-phase confirmatory Phase 3 or comparative-effectiveness trials. Interventions may include small molecules, biologics, devices, surgical, behavioral, diet-based and rehabilitation therapies.

Supports two tracks to build clinical and translational research capacity in IDeA states: CTR-D for workforce and infrastructure development and CTR-N for statewide or multi-state networks that expand clinical research infrastructure and coordinate research activities. Limited competition; all participating organizations must be located in IDeA-eligible states.

Private-foundation portfolio funding research on emotional/behavioral challenges, participation, and quality of life after spinal cord injury (SCI); two-step LOI then invited full application via ProposalCentral; PI must hold a doctoral/terminal degree. NOTE: 2027-cycle LOI closed Mar 5, 2026; invited full applications due mid/late 2026. Next open entry point is the 2028 LOI (~Q1 2027). Recurring annual — track for next cycle.

Private-foundation portfolio funding mechanistic, preclinical, translational, and clinical spinal cord injury (SCI) research (Postdoctoral Fellowship, Pilot, and Senior Research categories); two-step LOI then invited full application via ProposalCentral. NOTE: 2027-cycle LOI (opened Apr 17, 2026) appears closed per the cycle calendar; invited full applications due Nov 12, 2026. Next open entry point is the 2028 LOI (~Q2 2027). Recurring annual — track for next cycle.

Supports bold, early-stage health technology research led by early-career PIs (academic, nonprofit, or industry) within 8 years of their first terminal degree, across 16 topics including neuroscience, inflammation, infectious disease, and medical countermeasures. Solution summaries are due Oct 30, 2026 (Proposers' Day Oct 13; register by Oct 12).

Supports a research network generating real-world evidence on the effectiveness, safety, and implementation of rapid-acting psychotropic drugs such as ketamine, esketamine, and psilocybin for serious mental illness. Nonprofits are eligible and the topic aligns with military mental health.

Supports mechanistic research on how metal exposures alter biological processes, including absorption, transport, immune effects, placental transfer, and central nervous system access.

Supports first-in-human and early-stage clinical studies of recording and/or stimulating devices to treat central nervous system disorders, with a companion UG3/UH3 (RFA-NS-25-021). Recurring program reissued roughly every 1 to 2 years.

Supports creative basic research by early-career scientists and engineers who received their PhD on or after April 1, 2019, in topic areas of the current AFOSR BAA. The PI must be a full-time employee of the proposing organization; required white papers are due Oct 9, 2026 and full proposals Dec 4, 2026.

Supports clinical research sites for the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), which runs clinical trials and biomarker validation studies for neurological disorders in adult and pediatric populations.

Supports integration and dissemination of BRAIN Initiative neurotechnologies into research and training at institutions with limited NIH Research Project Grant funding, with two-way knowledge transfer between investigator and technology disseminator.

Supports exceptionally creative early stage investigators pursuing bold, high-risk mechanistic research in addiction science (genetic, molecular, circuit, pharmacological, behavioral, and cognitive processes underlying substance use disorders), including investigators new to the field.

Supports development of innovative technologies to enable acquisition of biomedical knowledge, including instruments, software, algorithms, reagents, and engineered biological tools, with emphasis on advancing proof-of-concept approaches into validated working prototypes. Best suited for high-risk projects focused on overcoming significant technical barriers and demonstrating broad utility, rather than applying the technology to specific biological questions.

ARPA-H Exploratory Topic to generate region-specific graftable precursor brain tissue and demonstrate surgical engraftment, extending beyond the neocortex (FRONT) to hippocampus, thalamus, brainstem, cerebellum, and more.

Funds Core Platform Teams to build persistent, multi-arm adaptive platform trials that combine simulation, real-time inference, and AI-enabled operations to evaluate drugs and biologics faster, cheaper, and with fewer participants. Teams must stand up a single-disease platform with at least three intervention arms, a multi-site clinical network, and an FDA-engaged Master Protocol.

Supports applied research on human health and performance countermeasures, exploration medical capability, human factors and behavioral performance, and space radiation for NASA's Human Research Program. Recurring umbrella NOFO with topic appendices released through the year; all categories of U.S. institutions are eligible, and the next cycle date is not yet confirmed.

Supports advanced technology development to protect deployed military personnel from arthropod vectors of disease (tick-borne pathogens, mosquito-borne arboviruses, nuisance biters, and emerging threats such as New World Screwworm), including new or reformulated insecticides, personal protection technologies, and improved pesticide application equipment. Unrestricted eligibility, no cost share; pre-applications due Nov 20, 2026 (5:00 p.m. ET), with full applications (by invitation) due Mar 17, 2027.

BARDA's Protection Before Day One (PBD1) Draft RPP, issued through the Rapid Response Partnership Vehicle (RRPV), seeks RRPV member vaccine developers with broadly protective influenza vaccine candidates that (1) provide seasonal protection and cross-protection against pandemic-potential strains; (2) can reach IND readiness with scalable manufacturing; and (3) are ready to advance into clinical evaluation.

Funds teams to understand how autism develops across the lifespan and to act on that knowledge earlier and more precisely, through multi-factor trajectory analysis, data integration, precision interventions, and everyday assistive technologies.

Seeks information papers from AI, machine learning, and NLP developers, clinical coding vendors, and EHR integrators with solutions that (1) automatically identify or recommend ICD-10-CM external cause of injury codes from free-text clinical documentation; (2) integrate with MHS GENESIS and other military health record systems; and (3) improve injury surveillance without adding clinician burden.